Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Monday 16 January, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 2974U
GlaxoSmithKline PLC
16 January 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

406.772 (personal contribution)

£15.66

406.759 (personal contribution)

£15.66

203.865 (personal contribution)

£15.66

203.865 (personal contribution)

£15.66

510.713 (personal contribution)

£15.66

406.772 (matching shares)

£15.66

406.759 (matching shares)

£15.66

203.865 (matching shares)

£15.66

203.865 (matching shares)

£15.66

510.713 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

3,463.948

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

89.065 (personal contribution)

£15.66

89.065 (personal contribution)

£15.66

71.015 (personal contribution)

£15.66

71.015 (personal contribution)

£15.66

175.863 (personal contribution)

£15.66

175.850 (personal contribution)

£15.66

89.065 (matching shares)

£15.66

89.065 (matching shares)

£15.66

71.015 (matching shares)

£15.66

71.015 (matching shares)

£15.66

175.863 (matching shares)

£15.66

175.850 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,343.746

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

79.620 (personal contribution)

£15.66

79.607 (personal contribution)

£15.66

52.007 (personal contribution)

£15.66

52.007 (personal contribution)

£15.66

119.484 (personal contribution)

£15.66

79.620 (matching shares)

£15.66

79.607 (matching shares)

£15.66

52.007 (matching shares)

£15.66

52.007 (matching shares)

£15.66

119.484 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

765.45

£15.66

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

192.213 (personal contribution)

£15.66

76.874 (personal contribution)

£15.66

99.193 (personal contribution)

£15.66

99.180 (personal contribution)

£15.66

232.242 (personal contribution)

£15.66

232.229 (personal contribution)

£15.66

192.213 (matching shares)

£15.66

76.874 (matching shares)

£15.66

99.193 (matching shares)

£15.66

99.180 (matching shares)

£15.66

232.242 (matching shares)

£15.66

232.229 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,863.862

£15.66

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

36.414 (personal contribution)

£15.66

36.414 (personal contribution)

£15.66

85.869 (personal contribution)

£15.66

85.869 (personal contribution)

£15.66

36.414 (matching shares)

£15.66

36.414 (matching shares)

£15.66

85.869 (matching shares)

£15.66

85.869 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

489.132

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

116.783 (personal contribution)

£15.66

171.654 (personal contribution)

£15.66

202.916 (personal contribution)

£15.66

202.916 (personal contribution)

£15.66

116.783 (matching shares)

£15.66

171.654 (matching shares)

£15.66

202.916 (matching shares)

£15.66

202.916 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,388.538

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

72.618 (personal contribution)

£15.66

72.605 (personal contribution)

£15.66

58.351 (personal contribution)

£15.66

58.351 (personal contribution)

£15.66

109.284 (personal contribution)

£15.66

109.284 (personal contribution)

£15.66

72.618 (matching shares)

£15.66

72.605 (matching shares)

£15.66

58.351 (matching shares)

£15.66

58.351 (matching shares)

£15.66

109.284 (matching shares)

£15.66

109.284 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

960.986

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.01

125.340 (personal contribution)

$39.01

125.327 (personal contribution)

$39.01

78.047 (personal contribution)

$39.01

78.047 (personal contribution)

$39.01

128.475 (personal contribution)

$39.01

128.475 (personal contribution)

$39.01

125.340 (matching shares)

$39.01

125.327 (matching shares)

$39.01

78.047 (matching shares)

$39.01

78.047 (matching shares)

$39.01

128.475 (matching shares)

$39.01

128.475 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,327.422

$39.01

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

90.103 (personal contribution)

£15.66

78.542 (personal contribution)

£15.66

78.530 (personal contribution)

£15.66

159.879 (personal contribution)

£15.66

159.879 (personal contribution)

£15.66

90.103 (matching shares)

£15.66

78.542 (matching shares)

£15.66

78.530 (matching shares)

£15.66

159.879 (matching shares)

£15.66

159.879 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,133.866

£15.66

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882   

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

54.266 (personal contribution)

£15.66

53.347 (personal contribution)

£15.66

97.819 (personal contribution)

£15.66

54.266 (matching shares)

£15.66

53.347 (matching shares)

£15.66

97.819 (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

410.864

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.01

50.726 (personal contribution)

$39.01

50.726 (personal contribution)

$39.01

40.386 (personal contribution)

$39.01

40.386 (personal contribution)

$39.01

90.932 (personal contribution)

$39.01

90.932 (personal contribution)

$39.01

50.726 (matching shares)

$39.01

50.726  (matching shares)

$39.01

40.386  (matching shares)

$39.01

40.386  (matching shares)

$39.01

90.932  (matching shares)

$39.01

90.932  (matching shares)

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

728.176

$39.01

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, Pharmaceuticals R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.66

161.014 (personal contribution)

£15.66

161.001 (personal contribution)

£15.66

115.614 (personal contribution)

£15.66

115.614 (personal contribution)

£15.66

188.068 (personal contribution)

£15.66

188.068 (personal contribution)

£15.66

161.014 (matching shares)

£15.66

161.001  (matching shares)

£15.66

115.614 (matching shares)

£15.66

115.614 (matching shares)

£15.66

188.068 (matching shares)

£15.66

188.068 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,858.758

£15.66

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHVQLFFDFFLBBB

a d v e r t i s e m e n t